At 6:22 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading highe ...

Core Viewpoint - Emergent BioSolutions, Inc. is discussing its operational and financial results for Q4 and the full year of 2025 during the earnings conference call [2]. Group 1: Financial Performance - The earnings call will cover both operational and financial results for the fourth quarter and the entire year of 2025 [2]. - The company may discuss non-GAAP financial measures to provide greater transparency regarding its operating performance [4]. Group 2: Forward-Looking Statements - Emergent may make projections and forward-looking statements related to its business and future performance, which are based on current intentions and beliefs [3]. - Any forward-looking statement is only valid as of the date of the conference call, and the company does not commit to updating these statements unless required by law [3].

Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsFrank Vargo - TreasurerJoe Papa - President and CEORich Lindahl - EVP and CFOOperatorPlease be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Frank Vargo, Treasurer. Please go ahead.Frank VargoGood afternoon, everyone. Thank you for joining today as Emergent discusses their operational and financial results for the fourth quart ...

Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Company ParticipantsFrank Vargo - TreasurerJoe Papa - President and CEORich Lindahl - EVP and CFOOperatorPlease be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Frank Vargo, Treasurer. Please go ahead.Frank VargoGood afternoon, everyone. Thank you for joining today as Emergent discusses their operational and financial results for the fourth quart ...

Emergent BioSolutions (NYSE:EBS) Q4 2025 Earnings call February 26, 2026 05:00 PM ET Speaker2Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Frank Vargo, Treasurer. Please go ahead.Speaker0Good afternoon, everyone. Thank you for joining today as Emergent discusses their operational and financial results for the fourth quarter and full year of 2025. As is customary, today's call is open to all participants. The call is bei ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-33137 EMERGENT BIOSOLUTIONS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 14-1902018 | | --- | --- | | (State or Oth ...

Our Mission: Protect and Save Lives February 26, 2026 1 Safe Harbor Statement/Trademarks This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. All statements, other than statements of historical fact, including statements regarding the future performance of the Company or any of our businesses, our business strategy, future operations, future financial position, future revenues and earnings, our ability to achieve the ob ...

EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS GAITHERSBURG, Md., February 26, 2026—Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2025. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," said Joe Papa, president and CEO of Emergent. " ...

Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 ...

WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and C ...